IP Library › Granted Patent US 12,569,542
Granted Patent B2
US 12,569,542 · App. 18/064,793 · Granted Mar 10, 2026

Treatment of cancer with immune stimulators

Inventors: Robert S. King (Fremont, CA); Cynthia W. Tuthill (Hercules, CA); Friedhelm Blobel (Foster City, CA)
Assignee: SCICLONE PHARMACEUTICALS INTERNATIONAL (SG) PTE. LTD.
A61K38/2292A61K31/165A61K31/44A61K31/655A61K38/193A61K38/2046A61K38/21A61K39/39558A61K45/06A61P35/00A61P35/04C07K16/2818C07K2317/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,569,542
App. No.
18/064,793
Granted
Mar 10, 2026
Kind
B2
Abstract

The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and/or optionally one or more additional anti-cancer agents.

Claims (10)

1 . A method of treating cancer or a metastasis thereof in a subject comprising administering a therapeutically effective amount of an alpha thymosin peptide and a therapeutically effective amount of a checkpoint protein inhibitor, wherein the cancer is melanoma.

2 . The method of claim 1 , wherein the subject is a human.

3 . The method of claim 1 , wherein the checkpoint protein inhibitor comprises a programmed cell death-1 (PD-1) inhibitor.

4 . The method of claim 1 , wherein the alpha thymosin peptide is thymosin alpha 1 (TA1).

5 . The method of claim 1 , wherein the method further comprises administering a chemotherapeutic agent to the subject.

6 . The method of claim 5 , wherein the chemotherapeutic agent is dacarbazine (DTIC) or cisplatin.

7 . The method of claim 1 , wherein the alpha thymosin peptide is administered to the subject during at least a portion of the treatment at a dosage within a range of about 0.1-10 mg/day.

8 . The method of claim 1 , wherein the dosage of the alpha thymosin peptide is within a range of about 0.5-10 mg/day.

9 . A method of treating cancer or a metastasis thereof in a subject comprising administering a therapeutically effective amount of an alpha thymosin peptide, wherein the subject has been administered with a therapeutically effective amount of a checkpoint protein inhibitor, wherein the cancer is melanoma.

10 . The method of claim 9 , wherein the checkpoint protein inhibitor comprises a programmed cell death-1 (PD-1) inhibitor.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2024
From: SCICLONE PHARMACEUTICALS LLC
To: SCICLONE PHARMACEUTICALS INTERNATIONAL LTD.
Reel/Frame 066639/0534 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2024
From: SCICLONE PHARMACEUTICALS INTERNATIONAL LTD.
To: SCICLONE PHARMACEUTICALS INTERNATIONAL (SG) PTE. LTD.
Reel/Frame 066730/0332 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2023
From: KING, ROBERT S.; TUTHILL, CYNTHIA; BLOBEL, FRIEDHELM
To: SCICLONE PHARMACEUTICALS, INC.
Reel/Frame 063037/0584 →
CHANGE OF NAME Recorded Mar 20, 2023
From: SCICLONE PHARMACEUTICALS, INC.
To: SCICLONE PHARMACEUTICALS LLC
Reel/Frame 063122/0821 →
Continuity (6)
Continuation 16736211 · Jan 7, 2020
Continuation 15641550 · Jul 5, 2017
Continuation 14918675 · Oct 21, 2015
Provisional Application 62215433 · Sep 8, 2015
Provisional Application 62066862 · Oct 21, 2014
Related Publication 20230285513A1 · Sep 14, 2023
References Cited (35)
US 8008449B2 · Korman et al. · 2011 [cited by applicant]
US 9724395B2 · King et al. · 2017 [cited by applicant]
US 11571465B2 · King et al. · 2023 [cited by applicant]
US 20050049191A1 · Rudolph et al. · 2005 [cited by applicant]
US 20080300166A1 · Tuthill et al. · 2008 [cited by applicant]
US 20090217400A1 · Carmi et al. · 2009 [cited by applicant]
US 20100092499A1 · Moviglia et al. · 2010 [cited by applicant]
US 20160106812A1 · King et al. · 2016 [cited by applicant]
US 20180161399A1 · King et al. · 2018 [cited by applicant]
US 20200289618A1 · King et al. · 2020 [cited by applicant]
CN 101591397A · 2009 [cited by applicant]
CN 103458681A · 2013 [cited by applicant]
WO WO2006062917A2 · 2006 [cited by applicant]
WO WO2009075813A1 · 2009 [cited by applicant]
WO WO2009076587A1 · 2009 [cited by applicant]
WO WO2009079338A1 · 2009 [cited by applicant]
WO WO2014036412A2 · 2014 [cited by applicant]
Boomer et al., “The changing immune system in sepsis: Is individualized immunomodulatory therapy the answer?,” Virulence 5:1, 45-56; Jan. 1, 2014. [cited by applicant]
Economopoulou et al., “Histone H2AX is integral to hypoxia-driven neovascularisation,” Nature Medicine 15(5):528-536 (2009). [cited by applicant]
Garaci et al., Thymosin a1 in combination with cytokines and chemotherapy for the treatment of cancer. Int Immunopharmacol. 3(8):1145-1150 (2003). [cited by applicant]
Guixiang Qin,“Reconstruct recombination of LC-1 single-chain antibody with thymosin 1,” Journal of Qinghai Normal University (Natural Science Edition) No. 01 (2008). [cited by applicant]
International Search Report based on International Patent Application No. PCT/US2015/056609, mailed on Mar. 4, 2016. [cited by applicant]
Kharkevich D.A. Pharmacology / Textbook, 2010, 10th edition, pp. 72-82. [cited by applicant]
King, R.S., et al., “Evaluation of thymosin 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis,” Expert Opin Biol Ther., 15(1):S41-49 (2015). [cited by applicant]
Maio, M., et al., “Large Randomized Study of Thymosin 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic Melanoma,” 28(10):1780-1787 (2010). [cited by applicant]
Mangana et al., Sorafenib in melanoma, Exp. Opin. Investig. Drugs, 21, 557-568 (2012). [cited by applicant]
Meisel et al., “Granulocyte-Macrophage Colony-stimulating Factor to Reverse Sepsis-associated Immunosuppression” American Journal of Respiratory and Critical Care Medicine, 180(7): 640-648 (2009). [cited by applicant]
NIH-NCT 01295827 Feb. 15, 2011, 24 pages. [cited by applicant]
NIH-NCT 01375842 Apr. 17, 2011, 12 pages. [cited by applicant]
Payen, D., et al., “Immunotherapy—a potential new way forward in the treatment of sepsis,” Critical Care 17:118 (2013), 2 pages. [cited by applicant]
Pellegrini et al., “Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies,” Nature Medicine 15:528-536 (2009). [cited by applicant]
Shrivastava, P., et al., “Effect of Thymosin Alpha 1 on the Antitumor Activity of Tumor-Associated Macrophage-Derived Dendritic Cells,” Journal of Biomedical Science, 2004, vol. 11(5), pp. 623-630. [cited by applicant]
Wu et al., “Antitumor Effect of Interleukin 7 in Combination with Local Hyperthermia in Mice Bearing B16a Melanoma Cells,” Stem Cells 1195):412-421 (1993). [cited by applicant]
Wu, J., et al., “The efficacy of thymosin alpha 1 for severe sepsis (ETASS): A multicenter, single-blind, randomized and controlled trial,” Critical Care 2013, 13 pages. [cited by applicant]
Xiaochen Wang, “Application of synthetic thymosin Zadaxin in tumor, ”Journal of Practical Oncology No. 02 (2003), 5 pages with machine English translation of Summary Paragraph. [cited by applicant]